Agreed ... but it is is far from common-sense to understand conceptually why in a P3 confirmatory trial you have a hierarchical structure of outcomes. And when the primary outcome fails statistical significance on your secondary outcomes is meaningless.
You would have to write a book to explain why this is so.
But on your second point about a terrible choice of outcomes … I would disagree agree slightly. The outcomes for CHF and LBP were not bad per se. Rather it was the process that generated them which was flawed. So I agree with dplanes point about overconfidence on weak P2 results.
The trouble is running P3 trials as if they were exploratory P2 trials – to learn as you go and to generate interesting sub-group efficacy signals on different endpoints for later testing in ……more P3 trials is completely un-viable.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-290
-
- There are more pages in this discussion • 814 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 39558 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 21776 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 39558 | 1.300 |
3 | 26433 | 1.295 |
6 | 108207 | 1.290 |
2 | 47468 | 1.285 |
3 | 10889 | 1.280 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 21776 | 3 |
1.315 | 57441 | 5 |
1.320 | 2500 | 1 |
1.325 | 61160 | 4 |
1.330 | 15000 | 2 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |